EX VIVO DRUG RESPONSE PROFILING AND OUTCOME PREDICTION IN LUNG ADENOCARCINOMA
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing.
• Patient's written informed consent present.
• Ability to understand the nature of the trial and the trial related procedures and to comply with them.
Locations
Other Locations
Israel
Sheba Medical Center
RECRUITING
Ramat Gan
Time Frame
Start Date: 2023-06-14
Estimated Completion Date: 2030-01-01
Participants
Target number of participants: 400
Treatments
Patients with diagnosis of a Lung adenocarcinoma with the need of pleural drainage due to MPE
Related Therapeutic Areas
Sponsors
Leads: Sheba Medical Center